Direct Inhibition of Expressed Cardiac L- and T-type Calcium Channels by Igg from Mothers Whose Children Have Congenital Heart Block
Overview
Authors
Affiliations
Background: Congenital heart block (CHB) is a disease that affects the offspring of mothers with autoimmune diseases. We recently reported that maternal sera containing antibodies against SSA/Ro and SSB/La ribonucleoproteins (positive IgG) inhibited L-type Ca current in isolated cardiac myocytes and induced sinus bradycardia in a murine model of CHB. The direct interaction of positive IgG with L-type Ca channel proteins and the possible inhibition of T-type Ca current that could account for the sinus bradycardia remain unknown.
Methods And Results: The 2-electrode voltage-clamp technique was used to record currents via L-type (I(Ba)-alpha(1C) or I(Ba)-alpha(1C)+beta(2a)+alpha(2)/delta) and T-type (I(Ba)-alpha(1H)) Ca channels, Na channels (I(Na)-hH1), and K channels (I(Ks)-minK+KvLQT1) expressed in Xenopus oocytes. Positive IgG (350 microgram/mL) inhibited I(Ba)-alpha(1C) by 50.6+/-4.7% (P<0.01) and I(Ba)-alpha(1C)+beta(2a)+alpha(2)/delta by 50.9+/-4.2% (P<0.01); I(Ba)-alpha(1H) was reduced by 18.9+/-1.0% (P<0.01). Immunoblot data show cross-reactivity of positive IgG with alpha(1C) subunit. Pretreatment of oocytes with atropine (1 micromol/L) or acetylcholine (10 micromol/L) did not affect the inhibitory effect of IgG on I(Ba)-alpha(1C) and I(Ba)-alpha(1C)+beta(2a)+alpha(2)/delta (P<0.05). Positive IgG had no effect, however, on either I(Na)-hH1 or I(Ks)-minK+KvLQT1.
Conclusions: Positive IgG inhibited expressed L-type I:(Ba) and cross-reacted with the alpha(1C) subunit in Xenopus oocytes, providing strong evidence that maternal antibodies interact directly with the pore-forming alpha(1)-subunit of Ca channels. In addition, we show for the first time that positive IgG also inhibited T-type I(Ba) but not I(Na)-hH1 or I(Ks)-minK+KvLQT1. This could provide, in part, the ionic basis of sinus bradycardia reported in animal models of CHB and clinically in humans.
Fleischer S, Nash T, Tamargo M, Lock R, Venturini G, Morsink M Nat Cardiovasc Res. 2024; 3(9):1123-1139.
PMID: 39195859 PMC: 11399098. DOI: 10.1038/s44161-024-00525-w.
Gamazo-Herrero J, Medina-Luezas J, Cusacovich I, Martin-Asenjo M, Gonzalez-Montagut-Gomez C, Sanchez-Gonzalez M J Clin Med. 2024; 13(12).
PMID: 38930039 PMC: 11204400. DOI: 10.3390/jcm13123510.
Fleischer S, Nash T, Tamargo M, Lock R, Venturini G, Morsink M bioRxiv. 2024; .
PMID: 38559188 PMC: 10979865. DOI: 10.1101/2024.03.07.583787.
Sulu A, Kafali H, Kamali H, Genc S, Onan I, Haydin S Anatol J Cardiol. 2023; 27(2):106-112.
PMID: 36747457 PMC: 9900412. DOI: 10.14744/AnatolJCardiol.2022.2235.
Anti-Ro/SSA Antibodies and the Autoimmune Long-QT Syndrome.
Lazzerini P, Laghi-Pasini F, Boutjdir M, Capecchi P Front Med (Lausanne). 2021; 8:730161.
PMID: 34552948 PMC: 8450397. DOI: 10.3389/fmed.2021.730161.